Genmab, Seagen say phase three of innovaTV 301 trial met primary endpoint
04/09/2023 20:29
Sept 4 (Reuters) - Genmab GMAB.CO GMAB.O and Seagen SGEN.O on Monday said that the phase three of their innovaTV 301 global trial in recurrent or metastatic cervical cancer patients met its primary endpoint of overall survival. (Reporting by Granth Vanaik in Bengaluru, Editing by Rosalba O'Brien) ((Granth.Vanaik@thomsonreuters.com; Twitter: https://twitter.com/Vanaik_Granth;))